Change in number of shares in Brighter AB.
Conversion of convertible notes into shares under the Convertible Notes issued under the financing agreement announced on April 26.
The number of Notes converted on November 10, 2017 was 25. The number of Notes remaining under the third Tranche for future conversion is 78. The number of shares and the number of votes before the conversion was 63,863,063. Through the conversion, the number of shares and the number of votes have increased by 261,506. The total number of shares and the total number of votes after the conversion amount to 64,124,569.
For terms and conditions of the Notes, please visit:
http://brighter.se/en/investors/documents/.
For more information, please contact:
Truls Sjöstedt, CEO
Tel: +46 709 73 46 00
Email: truls.sjostedt@brighter.se
Ann Zetterberg, CFO
Tel: +46 708 37 21 23
Email: ann.zetterberg@brighter.se
About Brighter AB (publ)
Brighter develops solutions for data-driven and mobile health services. Through its intellectual property and its first launch Actiste®, the company creates a more efficient care chain with focus on the individual. The goal is to simplify, streamline and enhance the information flow of relevant and reliable data between the patient and health care professionals. Brighter is initially focused on diabetes care, but there are opportunities in the future to operate on a broader level, spanning more diseases and treatment approaches. This is done through The Benefit Loop®, Brighter’s cloud-based service that continuously collects, analyzes and shares data on the user's terms.
The Company's shares are listed on NASDAQOMX First North/BRIG. Brighter’s Certified Adviser on Nasdaq OMX First North is Remium Nordic AB +46 (0)8 – 454 32 50, CorporateFinance@remium.com, www.remium.com.
This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 13:45 CET on November 13, 2017.